Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
2024 · Intensive Care Medicine · 63 citations
https://doi.org/10.1007/s00134-023-07271-w
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
44
Papers
2.0K
Citations
19
h-index
27
i10-index
David W. Boldt is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Sepsis Diagnosis and Treatment & Blood Pressure and Hypertension Studies & Respiratory Support and Mechanisms. The author has an h-index of 19, co-authored 38 publications.
https://doi.org/10.1007/s00134-023-07271-w
https://doi.org/10.1186/s13054-018-2225-4
https://doi.org/10.1186/s13613-023-01227-5
Click to start Chat